Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | RXRG | P48443 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23318790 | 0.84 | GAA (0.42) | CYP2C19ALDH1A1GAAMAPTLMNA | |
| SCHEMBL10646361 | 0.83 | CYP2C19 (0.44) | CYP2C19ALDH1A1GAAMAPTLMNA | |
| SCHEMBL179444 | 0.83 | CYP2C19 (0.44) | CYP2C19ALDH1A1GAAMAPTLMNA | |
| SCHEMBL12732707 | 0.83 | CA12 (0.47) | CYP2C19ALDH1A1GAAMAPTLMNA | |
| SCHEMBL1688243 | 0.82 | MAPT (0.50) | CYP2C19ALDH1A1MAPTKDM4ERAB9A | |
| SCHEMBL14167831 | 0.82 | CYP19A1 (0.49) | CYP2C19ALDH1A1GAAMAPTLMNA | |
| SCHEMBL13930887 | 0.81 | CYP2C19 (0.43) | CYP2C19ALDH1A1GAAMAPTLMNA | |
| SCHEMBL29436012 | 0.80 | CA2 (0.50) | CYP2C19ALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL179467 | 0.80 | CA2 (0.50) | CYP2C19ALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL21892239 | 0.79 | GAA (0.41) | CYP2C19ALDH1A1GAAMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11773122-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES. INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773122-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES. INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230250117-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-07-26 | — | — | US | disclosed |
| US-7230132-B2 | Aryl N-cyanoguanidines and methods related thereto | MIGENIX CORP. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | TIMMER RICHARD T | 2007-02-22 | — | — | US | disclosed |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | TIMMER RICHARD T | 2007-02-22 | — | — | US | disclosed |
| CN-1911915-A | Lactam compound and medicinal use thereof | AJINOMOTO KK (JP) | 2007-02-14 | — | — | CN | disclosed |
| CN-1269818-C | Lactam compounds and pharmaceutical use thereof | AJINOMOTO KK (JP) | 2006-08-16 | — | — | CN | disclosed |
| CN-1487940-A | Lactam compounds and pharmaceutical use thereof | ֮����ʽ���� | 2004-04-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CYP2C19 561/4885ALDH1A1 344/4885GAA 139/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CYP2C19 4866/4885ALDH1A1 4701/4885GAA 1534/4885 |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | CYP2C19 4826/4885ALDH1A1 4407/4885GAA 852/4885 |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | CYP2C19 3796/4885ALDH1A1 2911/4885GAA 4130/4885 |
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | CYP2C19 2942/4885ALDH1A1 3639/4885GAA 862/4885 |
| US-20230250117-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | CYP2C19 2942/4885ALDH1A1 3639/4885GAA 862/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | CYP2C19 1191/4885ALDH1A1 1374/4885GAA 773/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | CYP2C19 3141/4885ALDH1A1 1079/4885GAA 4203/4885 |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | CYP2C19 2942/4885ALDH1A1 3639/4885GAA 862/4885 |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | CDKL2, CDK2, CDKL1 | CYP2C19 2608/4885ALDH1A1 4225/4885GAA 3243/4885 |
| US-11773122-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | CYP2C19 2942/4885ALDH1A1 3639/4885GAA 862/4885 |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | CYP2C19 490/4885ALDH1A1 1828/4885GAA 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.